EU Proposal To Restrict Microplastics In Pharmaceutical Ingredients Has US Excipient Industry On Edge
Executive Summary
A proposal by the European Chemicals Agency that would restrict the use of microplastics in pharmaceuticals in the EU under its REACH regulation has come under attack by the US excipient industry. Officials argue that the proposal is misguided in that it considers all polymers to be microplastics and would unnecessarily restrict the availability of medicines that contain polymers in formulations.
You may also be interested in...
ECHA’s Microplastic Ban Proposal Is ‘Brutally Misinformed’ – Cosmetics Europe
Cosmetics Europe’s Director-General John Chave discusses “a whole clutch of errors and misunderstandings” underlying ECHA’s proposal to prohibit use of intentionally added microplastics in cosmetics. According to the exec, the agency overestimates the prevalence and promise of natural/organic formulation while underestimating compliance costs by as much as 50%.
Program Participants Urge The FDA To Adopt Some Pharmaceutical Quality Metrics And Avoid Others
Site-based metrics praised; lot acceptance rates, invalidated OOS rates discouraged. Agency official admits some proposed metrics were “not the best.”
EU GMP Annex I Is A Top Priority For EMA While Industry Has Lingering Concerns
Questions about contamination control strategy raised as European Medicines Agency makes EU GMP Annex I revision a top priority in its 2021 work plan.